Original reporting and analysis on the stories shaping biotech.
A stealthy oncology startup just burst onto the scene with $100 million and a platform that claims to solve one of cancer drug development's oldest problems. The investors backing Stipple Bio read like a who's who of biotech venture capital, but the company hasn't even named its target yet.
Boehringer Ingelheim just named ADCs and T-cell engagers as its top M&A targets, adding another deep-pocketed buyer to oncology's most competitive shopping aisle. With nearly EUR 6.4 billion in annual R&D spending, the privately held pharma giant is about to make the bidding wars even more intense.
For 20 years, Hunter syndrome patients had a treatment that helped their bodies but couldn't reach their brains. Denali Therapeutics just changed that with the first enzyme replacement therapy engineered to cross the blood-brain barrier, and the FDA approved it early.
FDA Commissioner Marty Makary is rewriting the rules of drug approval: one trial instead of two, AI-powered reviews, and a new pathway for ultra-rare diseases. The biotech industry loves the vision, but Wall Street isn't sure the execution can keep up.
GSK raided Sanofi's bench to grab a 25-year vaccine veteran with 20-plus regulatory approvals under his belt. With mRNA rivals closing in fast, the timing tells you everything about how seriously GSK is taking the fight.
MIT and Recursion just open-sourced an AI model that predicts drug binding as accurately as the gold standard, but 1,000 times faster. It could reshape how the entire industry screens for new medicines.
Tecartus just became the first CAR-T cell therapy to convert from accelerated to full FDA approval, backed by a 91% response rate in relapsed mantle cell lymphoma. It's a milestone for one drug and a proof of concept for the entire cell therapy field.
A Beijing biotech founded in 2022 just raised $250 million in four months, with AstraZeneca, sovereign wealth funds, and top-tier VCs all piling in. The bet: an AI platform that could crack the code on a "Goldilocks" class of drugs most pharma companies can't figure out.
Gilead's once-weekly HIV pill was supposed to be a game-changer. Instead, the drug combination started attacking the very immune cells it was designed to protect, forcing the company to kill the late-stage trial. The $20.8 billion HIV franchise will survive, but the setback raises hard questions about long-acting oral treatments.
The Trump administration just announced 100% tariffs on imported brand-name drugs, but the fine print tells a very different story. With 13 companies already cutting confidential deals and generics completely exempt, analysts say only 4.4% of pharma imports will actually face the full rate.
The White House wants to cut $15.8 billion from HHS, including a $5 billion hit to NIH. Congress has killed proposals like this before, but the uncertainty alone is already doing damage to America's biotech pipeline.
For three decades, the global drug pipeline only grew. Now it's shrunk for the first time since the mid-1990s, dropping nearly 1,000 programs. The forces behind the reversal tell a bigger story about where biotech is headed.
A Beijing-based biotech just raised $250 million in six months without a single drug in human testing. Syneron Bio's AI-powered peptide platform has AstraZeneca, sovereign wealth funds, and top VCs all placing big bets on molecules that could hit 'undruggable' targets.
Beam Therapeutics' base-editing therapy for sickle cell disease just landed in the New England Journal of Medicine, and the results are turning heads: 31 patients treated, zero severe pain crises, and fetal hemoglobin levels that rival healthy carriers. This isn't just a win for one company; it's a credibility moment for a whole new class of gene editing.
The FDA approved Eli Lilly's Foundayo, an oral obesity pill you can take any time without food restrictions, at just $25/month with insurance. It's cheaper, easier, and could reshape the entire GLP-1 market that Novo Nordisk has dominated.
Biogen's Spinraza was losing ground to Zolgensma and Evrysdi in the SMA market. Then the FDA approved a high-dose version that works significantly better, and it could reshape how the industry thinks about dose optimization for genetic medicines.
The UK just became the only country with tariff-free pharmaceutical access to the U.S. market, dodging 100% duties that everyone else still faces. The price? A 25% hike in what the NHS pays for new drugs, and a template that could reshape global pharma negotiations.
The Trump administration just dropped 100% tariffs on patented drug imports, the most aggressive pharma trade action in modern history. The real story isn't the tariff itself; it's the coordinated strategy pairing trade policy with FDA overhauls to fundamentally rewire how America makes and approves its medicines.
A BAP1 gene mutation guarantees cancer but makes tumors less aggressive, confounding researchers for years. Now a two-drug combination has exploited that contradiction to shrink tumors across four cancer types in mice, and both drugs already have human safety data.
Alto Neuroscience killed its brain patch drug for schizophrenia after a Phase 2 miss that came down to a statistical photo finish. The company is pivoting to depression, but the failure spotlights why cracking cognitive symptoms in psychiatry remains one of biotech's hardest puzzles.
Merck just signed a deal worth up to $838 million with Infinimmune, a four-year-old startup that mines the human immune system for antibodies using AI. It's the latest sign that Big Pharma's antibody shopping spree is far from over.
Gilead pulled the plug on its weekly HIV pill trial after an FDA safety hold lasted nearly a year without resolution. The company's HIV empire isn't crumbling, but its "dosing optionality" strategy just lost a key option.
Join thousands of biotech professionals who start their day with our free, daily briefing.